AstraZeneca Laroprovstat/Rosuvastatin Fixed-Dose Combination Phase 3 Trial Starts September 15, 2026: LDL Cholesterol Study Design

AstraZeneca (AZN) has a Phase III cardiovascular-metabolic trial reaching its expected start date of September 15, 2026, according to trial registration data tracked by BioSniper since September 2, 2026. The study tests a fixed-dose combination of laroprovstat and rosuvastatin against rosuvastatin alone on LDL cholesterol in patients with hypercholesterolaemia. This preview summarizes the verified study design, what our data does not cover, and where the trial sits within AstraZeneca's exceptionally dense late-phase pipeline — for a company with a market capitalization of approximately $248.2 billion in our snapshot, the largest in our tracked universe.

The event

The trial in question is registered in our catalyst dataset as:

"A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients With Hypercholesterolaemia"

The expected start date — September 15, 2026, today — is recorded with "exact" date confidence, meaning it reflects the date stated in the registration rather than an estimate. As of publication, our data does not record an actual start (first-participant-in) confirmation, so the verified fact is the registered plan, not the fact of enrollment having begun.

What's verified

• Company: ASTRAZENECA PLC, ticker AZN, active listing status.
• Event type: Phase 3 trial start (Phase3_Start in our taxonomy).
• Expected date: September 15, 2026, "exact" confidence.
• First tracked: September 2, 2026 — the registration entered our dataset less than two weeks before the expected start.
• Design elements in the registered title: Phase III; randomised; double-blind; parallel-group; fixed-dose combination of laroprovstat/rosuvastatin; comparator rosuvastatin alone; endpoint low-density lipoprotein (LDL) cholesterol; population patients with hypercholesterolaemia.
• Company scale: Market capitalization of $248,203,771,904 in our snapshot.

What remains unknown

Our registration-derived record does not include several details readers will ask about, and we mark them UNKNOWN rather than guess:

• Enrollment size: not in our data.
• Number of sites or countries: not in our data, beyond "parallel-group" implying multi-arm multi-site conduct typical of the design — the title itself carries no geography.
• Primary endpoint formalities beyond LDL cholesterol: the registered title names LDL cholesterol as the effect measure; structured endpoint fields are otherwise empty in our record.
• Actual trial start: not yet recorded; only the expected date is verified.
• Trial outcome: UNKNOWN — this is a start event, not a readout.

Why a fixed-dose LDL combination matters on this calendar

Fixed-dose combinations of a novel agent with an established statin are a classic lifecycle strategy in cardiometabolic medicine: the registration pits laroprovstat/rosuvastatin directly against rosuvastatin monotherapy, which frames the regulatory question as incremental LDL lowering on top of standard of care. Our data captures the design skeleton exactly as registered; the strategic interpretation above is context, not a claim about results.

Platform context: AstraZeneca's Phase 3 engine

Our tracker holds 50 catalyst records for AstraZeneca — by far the deepest calendar in our coverage. Around this September 15 start, the late-phase neighborhood includes:

• Baxdrostat — Phase 3 start expected September 30, 2026: a randomized, double-blind, placebo-controlled study on ambulatory blood pressure in Chinese participants with uncontrolled hypertension on two or more antihypertensive medications without diuretics.
• Balcinrenone/dapagliflozin — Phase 3 start expected September 1, 2026 versus dapagliflozin alone on renal and cardiovascular outcomes in chronic kidney disease (stage 3b and 4).
• Elecoglipron — Phase 3 start expected August 28, 2026: the Elevate-HF study on cardiovascular outcomes in heart failure with preserved or mildly reduced ejection fraction (HFpEF and HFmrEF).
• Saruparib — Phase 3 start expected October 1, 2026 (EvoPAR-Prostate05), combined with androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer.
• Anifrolumab — a Phase 3b open-label 52-week study in Chinese patients with active moderate-severe systemic lupus erythematosus (expected September 4, 2026), a rollover study (ROSY-S, expected September 1, 2026), and a Phase 1 subcutaneous-versus-intravenous pharmacokinetics study (expected October 30, 2026).
• Datopotamab — a Phase 3 open-label adjuvant study (expected July 16, 2026).
• Camizestrant — SERAFA-1, a single-arm Phase 3b study (expected June 15, 2026).

The portfolio is rounded out by twelve tracked patent-expiry records on approved NDAs stretching from 2030 to 2042 — a reminder that this is a company whose commercial base funds one of the busiest Phase 3 calendars we track.

How to track it

• AstraZeneca company page — full catalyst calendar: https://biosniper.co/company/AZN
• This trial-start event page: https://biosniper.co/calendar/event/5801877

Bottom line

A registered Phase 3 start for a laroprovstat/rosuvastatin fixed-dose combination versus rosuvastatin in hypercholesterolaemia lands on September 15, 2026, with exact date confidence and a design that centers LDL cholesterol. The enrollment size, geography, and eventual results are unknown in our data. For AstraZeneca, it is one entry in a 50-record catalyst calendar — but a clean, registration-grounded window into how the company is positioning a novel LDL-lowering agent alongside a widely used statin.